Pharmacovigilance and kidney disease

What is it about?

Drugs and medical devices can cause adverse events as well as aiming to improve clinical outcomes. Patients with endstage renal failure are particularly at risk because of the complexity of the underlying pathophysiology, comorbidity and the potential for interactions. This area of clinical practice is reviewed in relationship to post-approval drug/device use and case examples given to stress the importance of pharmacovigilance and the need for all practitioners to report adverse events.

Featured Image

Why is it important?

This is an up to date review of pharmacovigilance theory and practice. It explores the specific unique issues in renal disease and uses a set of case studies to illustrate the importance and clinical benefits for adverse event reporting